secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001558370-24-000031
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics grants 177,000 RSUs to CEO and 20,000 RSUs to SVP in annual equity awards
--------------------------------------------------------------------------------

- CEO René Russo granted 177,000 restricted stock units effective Jan 1, 2024.
- SVP Kevin Brennan granted 20,000 restricted stock units effective same date.
- RSUs vest in four equal annual installments beginning Jan 1, 2025, subject to continued service.
- Awards granted under 2021 Stock Incentive Plan; form agreement filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024000031/0001558370-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024000031/xlo-20240101x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer